and

DAR GLOBAL AND ART DISTRICT REAL ESTATE DEVELOPMENT ANNOUNCE ‘MAD’, MUSCAT’S MARINE, ART & DIGITAL DISTRICT

MUSCAT, Oman, Dec. 8, 2025 /PRNewswire/ -- Dar Global (LSE: DAR), the London-listed luxury real estate developer, in partnership with…

40 minutes ago

Mantle “2025 RWApped”: A Year of Unstoppable MoMNTum and Global RWA Expansion

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- In 2025, Mantle entered a new phase of its evolution. What began as a high-performance…

41 minutes ago

Bybit and Circle Forge Strategic Partnership to Advance Global USDC Adoption

DUBAI, UAE, Dec. 8, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, today announced a strategic partnership…

41 minutes ago

SANY and Pony.ai Announce Mass-Production Readiness of Fourth-Generation Autonomous Heavy-Duty Truck

BEIJING, Dec. 8, 2025 /PRNewswire/ -- SANY Group announced that the fourth-generation autonomous heavy-duty truck co-developed by SANY Heavy Truck…

3 hours ago

Riyadh Air and IBM Partner to Launch World’s First AI-Native Airline

Riyadh Air's AI‑powered operations create agility across the business and unify employee and guest experiences, setting a new benchmark in…

3 hours ago

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…

17 hours ago

Olympic flame in Rome: IOC President praises Italys warmth and energy

06 December 2025 - When the flame for the Milano Cortina 2026 Olympic Winter Games lit the Piazza del Quirinale, the square in…

1 day ago

TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

December 06, 2025 17:30 ET  | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…

2 days ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard…

2 days ago

Yidan Prize Foundation connects global insights and local expertise at annual flagship Summit

500 changemakers from over 50 countries stand in solidarity with Hong Kong and co-create paths forward through educationHONG KONG, Dec.…

2 days ago